Clinical trials: Fusion of Joint
Psoriatic Arthritis, Axial Spondyloarthritis
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
- Trial name
- NCT07290036
- Testing
- Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
- Where
- 63 sites in United States, Bulgaria and 4 more
- Volunteers
- 392 people
- Sponsor
- UCB Biopharma SRL
Spondylitis, Ankylosing
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS).
- Trial name
- NCT01208207
- Testing
- Part I - etoricoxib 60 mg, Part I - etoricoxib 90 mg, Part I- naproxen 1000 mg
- Volunteers
- 1,015 people
- Sponsor
- Organon and Co
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Trial name
- C-AXSPAND (NCT02552212)
- Testing
- Certolizumab Pegol
- Where
- 105 sites in United States, Australia and 7 more
- Volunteers
- 317 people
- Sponsor
- UCB BIOSCIENCES GmbH
Bone Disease, Fracture Bone
Calcium Phosphate Cement Registry (CPC Registry)
CPC REGISTRY is a multi-center, international, prospective, open-label, observational study on the use of injectable calcium phosphate cements for the treatment of bone defects in adults.
- Conditions
- Bone Disease, Fracture Bone, Bone Cyst
- Trial name
- CPC (NCT02575352)
- Where
- 11 sites in France, Germany and 3 more
- Volunteers
- 500 people
- Sponsor
- Graftys SA
Spondylitis, Ankylosing
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
- Trial name
- MEASURE 3 (NCT02008916)
- Testing
- Secukinumab
- Where
- 57 sites in United States, Belgium and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis, Rheumatoid Arthritis
Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis
This study is designed to investigate whether non-invasive ultrasound (US) that is optimized for stimulation and can elicit an anti-inflammatory response in people with Inflammatory Arthritis as compared to a sham intervention.
- Conditions
- Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- NCT06555562
- Testing
- Ultrasound Stimulation, Non-active ultrasound stimulation
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Surf Therapeutics
Enthesitis Related Arthritis (ERA)
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
- Trial name
- NCT01166282
- Testing
- adalimumab
- Volunteers
- 46 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Axial Spondyloarthritis
Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis
The purpose of this trial is to demonstrate the clinical efficacy of GR1501 at week 16; and to demonstrate safety and tolerability of GR1501 compared to placebo in patients with Radiographic Axial Spondyloarthritis at week 16 and…
- Trial name
- NCT05881785
- Testing
- GR1501 low dose, GR1501 high dose
- Where
- China
- Volunteers
- 465 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Ankylosing Spondylitis
A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira
A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira
- Trial name
- NCT04135508
- Testing
- BAT1406, Humira
- Volunteers
- 554 people
- Sponsor
- Bio-Thera Solutions
Axial Spondyloarthritis, Psoriatic Arthritis
Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study
This was a multicenter, retrospective, and non-interventional study using secondary data captured in the Electronic Health Records (EHRs).
- Trial name
- NCT05677542
- Testing
- secukinumab
- Where
- 3 sites in Spain
- Volunteers
- 758 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Ankylosing Spondylarthritis
Yuflyma® (Adalimumab), Patient Experience After Switching
Patient preference and experience can impact patients' adherence and persistence regarding a treatment, especially when switching.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- YU-MATTER (NCT05427942)
- Testing
- Adalimumab
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Celltrion HealthCare France
Ankylosing Spondylitis
Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
The purpose of this study is to investigate the incidence of adverse events for patients with AS treated with Enbrel in usual care settings.
- Trial name
- NCT00227227
- Where
- Germany
- Volunteers
- 750 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Axial Spondyloarthritis
A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life
The primary purpose is to assess the effectiveness of certolizumab pegol in patients with axial spondyloarthritis under routine clinical practice.
- Trial name
- CIMAX (NCT02354105)
- Where
- 100 sites in Belgium, Germany and 4 more
- Volunteers
- 680 people
- Sponsor
- UCB Biopharma S.P.R.L.
Non-radiographic Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis
This study is to evaluate the efficacy and safety of SHR0302 in subjects with active non-radiographic axial spondyloarthritis.
- Trial name
- NCT05324631
- Testing
- SHR0302
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Axial Spondyloarthritis
A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)
To evaluate the efficacy of Brodalumab in axSpA (ankylosing spondylitis [AS] and non-radiographic axial spondyloarthritis [nr-axSpA]) subjects compared to placebo, as measured by the proportion of axSpA subjects achieving an…
- Trial name
- NCT02985983
- Testing
- Brodalumab
- Where
- 48 sites in Japan, South Korea and 1 more
- Volunteers
- 159 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Spondyloarthritis
SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue, and predictability of disease…
- Trial name
- SKIPPAIN (NCT03136861)
- Testing
- AIN457
- Where
- 66 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
The goal of this clinical trial is evaluating the efficacy and safety of Jitongning tablets in participant population. The main questions it aims to answer are: Based on the proportion of participants who achieved improvement in…
- Trial name
- NCT06000956
- Testing
- Jitongning tablets, a simulated agent of Jitongning tablets
- Where
- 10 sites in China
- Volunteers
- 408 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Ankylosing Spondylitis
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
This is a multi-center, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of ENIA11 in patients with ankylosing spondylitis.
- Trial name
- NCT02685904
- Testing
- ENIA11
- Where
- 6 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Mycenax Biotech Inc.
Sacroiliac Joint Disruption, Degenerative Sacroiliitis
Post-Market Feasibility Study of the Tenon Medical CATAMARAN™ SI Joint Fusion System
The purpose of this study is to evaluate the outcomes of patients with sacroiliac joint pain treated with the CATAMARAN SI Joint Fusion System.
- Trial name
- NCT05633888
- Testing
- CATAMARAN SI Joint Fusion System
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Tenon Medical
Axial Spondyloarthritis, Ankylosing Spondylitis
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA
- Trial name
- V-SPINE (NCT06526377)
- Testing
- vilamakitug
- Volunteers
- 150 people
- Sponsor
- XBiotech, Inc.